Global microRNA expression profiling in the liver biopsies of hepatitis B virus–infected patients suggests specific microRNA signatures for viral persistence and hepatocellular injury

Avishek Kumar Singh, Sheetalnath Babasaheb Rooge, Aditi Varshney, Madavan Vasudevan, Ankit Bhardwaj, Senthil Kumar Venugopal, Nirupama Trehanpati, Manoj Kumar, Robert Geffers, Vijay Kumar, Shiv Kumar Sarin – 30 November 2017 – Hepatitis B virus (HBV) can manipulate the microRNA (miRNA) regulatory networks in infected cells to create a permissive environment for viral replication, cellular injury, disease onset, and its progression.

Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long‐term follow‐up study

Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Ulf Hammar, Per Stål, Rolf Hultcrantz, Stergios Kechagias – 30 November 2017 – Most patients with nonalcoholic fatty liver disease (NAFLD) are overweight or obese. However, a significant proportion of patients have a normal body mass index (BMI), denoted as lean NAFLD. The long‐term prognosis of lean NAFLD is unclear. We conducted a cohort study of 646 patients with biopsy‐proven NAFLD. Patients were defined as lean (BMI < 25.0), overweight (BMI 25.0‐29.9), or obese (BMI ≥ 30.0) at the time of biopsy.

New insights into the role and mechanism of c‐Jun‐N‐terminal kinase signaling in the pathobiology of liver diseases

Sanda Win, Tin Aung Than, Jun Zhang, Christina Oo, Robert Win Maw Min, Neil Kaplowitz – 30 November 2017 – The c‐Jun‐N‐terminal‐kinase (JNK) family is highly conserved across species such as Drosophila, C. elegans, zebrafish and mammals, and plays a central role in hepatic physiologic and pathophysiologic responses. These responses range from cell death to cell proliferation and carcinogenesis, as well as metabolism and survival, depending on the specific context and duration of activation of the JNK signaling pathway.

Toward the elimination of hepatitis C in the United States

Sammy Saab, Long Le, Satvir Saggi, Vinay Sundaram, Myron J. Tong – 27 November 2017 – The emergence of effective direct‐acting antiviral (DAA) agents has reignited discussion over the potential for hepatitis C elimination in the United States. Eliminating hepatitis C will require a critical examination of technical feasibility, economic considerations, and social/political attention. Tremendous advancement has been made with the availability of sensitive diagnostic tests and highly effective DAAs capable of achieving sustained viral response (SVR) in more than 95% of patients.

Toward the elimination of hepatitis C in the United States

Sammy Saab, Long Le, Satvir Saggi, Vinay Sundaram, Myron J. Tong – 27 November 2017 – The emergence of effective direct‐acting antiviral (DAA) agents has reignited discussion over the potential for hepatitis C elimination in the United States. Eliminating hepatitis C will require a critical examination of technical feasibility, economic considerations, and social/political attention. Tremendous advancement has been made with the availability of sensitive diagnostic tests and highly effective DAAs capable of achieving sustained viral response (SVR) in more than 95% of patients.

Subscribe to